NasdaqGS - Nasdaq Real Time Price USD

Mesa Laboratories, Inc. (MLAB)

Trade MLAB on Coinbase
99.83 -1.44 (-1.42%)
At close: May 19 at 4:00:01 PM EDT
99.83 0.00 (0.00%)
After hours: May 19 at 4:10:04 PM EDT
Chart Range Bar
Loading chart for MLAB
Chart does not reflect overnight price.
  • Previous Close 101.27
  • Open 99.54
  • Bid 73.26 x 100
  • Ask 100.67 x 100
  • Day's Range 99.01 - 102.68
  • 52 Week Range 55.45 - 118.65
  • Volume 157,715
  • Avg. Volume 123,926
  • Market Cap (intraday) 551.542M
  • Beta (5Y Monthly) 0.94
  • PE Ratio (TTM) 153.58
  • EPS (TTM) 0.65
  • Earnings Date May 27, 2026
  • Forward Dividend & Yield 0.64 (0.63%)
  • Ex-Dividend Date May 29, 2026
  • 1y Target Est 104.50

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.

www.mesalabs.com

730

Full Time Employees

March 31

Fiscal Year Ends

Recent News: MLAB

View More

Performance Overview: MLAB

Trailing total returns as of 5/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

MLAB
27.39%
S&P 500 (^GSPC)
7.42%

1-Year Return

MLAB
15.15%
S&P 500 (^GSPC)
23.31%

3-Year Return

MLAB
35.93%
S&P 500 (^GSPC)
75.42%

5-Year Return

MLAB
57.86%
S&P 500 (^GSPC)
78.67%

Earnings Trends: MLAB

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 65.13M
Earnings --

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
20M
40M
60M
 

Analyst Insights: MLAB

View More

Analyst Price Targets

94.00 Low
104.50 Average
99.83 Current
115.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Latest Rating

Date 2/4/2026
Analyst Wells Fargo
Rating Action Maintains
Rating Equal-Weight
Price Action Raises
Price Target 83 -> 94
 

Statistics: MLAB

View More

Valuation Measures

Annual
As of 5/8/2026
  • Market Cap

    578.89M

  • Enterprise Value

    730.89M

  • Trailing P/E

    161.20

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.32

  • Price/Book (mrq)

    3.10

  • Enterprise Value/Revenue

    2.95

  • Enterprise Value/EBITDA

    14.71

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.51%

  • Return on Assets (ttm)

    2.47%

  • Return on Equity (ttm)

    2.18%

  • Revenue (ttm)

    247.54M

  • Net Income Avi to Common (ttm)

    3.73M

  • Diluted EPS (ttm)

    0.65

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    30.47M

  • Total Debt/Equity (mrq)

    91.07%

  • Levered Free Cash Flow (ttm)

    36.83M

Compare To: MLAB

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: MLAB

Research Reports: MLAB

View More

People Also Watch